Why the study?
Clinical risk scores like HEART, HEAR, and HET are used to risk-stratify ED patients with acute chest pain, but they often lack proper external validation.
How do the HEART, HEAR, and HET scores compare in predicting 30-day MACE in adult patients presenting to the ED with acute chest pain?
How do the HEART, HEAR, and HET scores compare in predicting 30-day MACE in adult patients presenting to the ED with acute chest pain?
The original HEART score outperforms its abridged versions (HEAR, HET) in identifying low-risk chest pain patients in the ED, suggesting existing scores should be recalibrated rather than abridged.
Supports HEART/HEAR/HET scores for 30-day MACE stratification in ED chest pain; leaves open optimal abridged version for safe discharge.
BACKGROUND AND IMPORTANCE: In the cohort of patients presenting to the emergency department (ED) with acute chest pain differentiating between those at high risk of major adverse cardiac event (MACE), and those who can safely be discharged, remains a challenge. The history, ECG, age, risk factors, troponin (HEART) score, as well as several abridged versions [history, ECG, age, risk factors (HEAR), history, ECG, troponin (HET)]. are commonly used for this purpose. As with many clinical risk scores, they might be useful, but often lack proper validation. We aimed to externally validate the HEART, HEAR, and HET scores in the setting of a high-volume tertiary care ED in a healthcare system without gatekeeping functions and thus a low-risk population. We further aimed to compare the prognostic performance (discrimination and calibration) of the scores to each other. DESIGN: External validation study. SETTINGS AND PARTICIPANTS: On the basis of a-priori sample size calculations, we prospectively included consecutive adult patients presenting to the ED with acute chest pain. OUTCOME MEASURES AND ANALYSIS: We assessed overall model performance, discrimination, and calibration of all scores, analyzed reclassification from the HEART score and performed decision curve analysis. MAIN RESULTS: A total of 3273 patients were included, 383 (12%) suffered MACE within 30 days. Classification differed significantly between scores (HEART: 810; 25% low risk; HET: 55; 2%; HEAR: 195; 6%), as did overall performance (area under the curve: 0.85, 0.80, and 0.79, respectively; P < 0.001). HEART score misclassified 7/810 patients (0.9%; 95% confidence interval: 0.4-1.8%) with MACE as low risk, HET 2/55 (3.6%, 0.9-13.8%), and HEAR 0/195, whereas 2087 (72%), 2837 (98%), and 2695 (93%) patients without MACE were erroneously not classified as low risk. CONCLUSION: The abridged scores fell short of their results in derivation studies, identifying only very few low-risk patients, and showing inferior model performance compared with the original HEART score. Instead of developing new scores, existing scores should be recalibrated to local population characteristics, as needed.
No takes yet. Share an insight, caveat, or question.
Niederer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: